D-0161-2025 Class II Ongoing

Recalled by Breckenridge Pharmaceutical, Inc — Berlin, CT

Recall Details

Product Type
Drugs
Report Date
January 1, 2025
Initiation Date
December 6, 2024
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
163,883 bottles

Product Description

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Reason for Recall

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Distribution Pattern

Nationwide in the US

Code Information

Lot # 222205C, exp. date 11/2025